Analyst Price Target is $35.25
▲ +55.44% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Alto Neuroscience in the last 3 months. The average price target is $35.25, with a high forecast of $50.00 and a low forecast of $24.00. The average price target represents a 55.44% upside from the last price of $22.68.
Current Consensus is
Moderate Buy
The current consensus among 10 contributing investment analysts is to moderate buy stock in Alto Neuroscience. This rating has held steady since September 2024, when it changed from a Buy consensus rating.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Read More
